{"nctId":"NCT02188784","briefTitle":"Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure","startDateStruct":{"date":"2014-09-03","type":"ACTUAL"},"conditions":["Chronic Heart Failure"],"count":225,"armGroups":[{"label":"Polysaccharide iron complex 150 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Polysaccharide Iron Complex 150 mg"]},{"label":"Placebo (for Polysaccharide Iron Complex 150 mg)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (for Polysaccharide Iron Complex)"]}],"interventions":[{"name":"Polysaccharide Iron Complex 150 mg","otherNames":["Feramax 150 mg"]},{"name":"Placebo (for Polysaccharide Iron Complex)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age \\>18 years\n2. Previous clinical diagnosis of heart failure with current New York Heart Association (NYHA) Class II-IV symptoms LVEF≤0.40 within 2 years prior to consent, and ≥3 months after a major change in cardiac status (i.e. CABG or CRT).\n3. Serum ferritin between 15-100 ng/ml or serum ferritin between 100-299 ng/ml with transferrin saturation \\<20%\n4. Hemoglobin 9.0-13.5 g/dL (males), 9-13.5 (females) at time of enrollment\n5. Stable evidence-based medical therapy for HF (including beta-blocker and ACE-inhibitor/ARB unless previously deemed intolerant, and diuretics as necessary) with \\</= 100% change in dose for 30 days prior to randomization\n\n   a. Changes in diuretic dose guided by a patient-directed flexible dosing program are considered stable medical therapy\n6. Willingness to provide informed consent\n\nExclusion Criteria:\n\n1. Presence of a neuromuscular, orthopedic or other non-cardiac condition that prevents the patient from exercise testing on a bicycle/treadmill ergometer and/or inability to achieve an RER ≥ 1.0 on screening/baseline CPET\n2. Severe renal dysfunction (eGFR\\< 20 ml/min/1.73m2)\n3. Severe liver disease (ALT or AST \\> 3x normal, alkaline phosphatase or bilirubin \\>2x normal)\n4. Gastrointestinal conditions known to impair Fe absorption (i.e. inflammatory bowel disease)\n5. Known active infection as defined by current use of oral or intravenous antimicrobial agents\n6. Documented active gastrointestinal bleeding\n7. Active malignancy other than non-melanoma skin cancers\n8. Anemia with known cause other than Fe deficiency or chronic disease\n9. Fe overload disorders (i.e. hemochromatosis or hemosiderosis)\n10. History of erythropoietin, IV or oral Fe therapy, or blood transfusion in previous 3 months.\n11. Current ventricular assist device\n12. Anticipated cardiac transplantation within the next 4 months\n13. Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy, acute myocarditis, constrictive pericarditis or tamponade\n14. Previous adverse reaction to study drug or other oral Fe preparation\n15. Known or anticipated pregnancy in the next 4 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Peak VO2 (ml/Min) (VO2 =Oxygen Consumption)","description":"To determine if oral Fe (Iron) polysaccharide is superior to oral placebo in improving functional capacity as measured by change in peak VO2 by CPET (Cardiopulmonary Exercise Testing) , of a broad population of patients with HFrEF (Heart Failure with Reduced Ejection Fraction) and Fe deficiency at 16 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.04","spread":"212.75"},{"groupId":"OG001","value":"3.90","spread":"190.24"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sub-maximal Exercise Capacity as Assessed by the 6 Minute Walk Test (6MWT)","description":"To determine the impact of oral Fe repletion on Submaximal exercise capacity as measured by 6MWT","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.65","spread":"95.89"},{"groupId":"OG001","value":"16.63","spread":"83.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.76","spread":"62.29"},{"groupId":"OG001","value":"30.94","spread":"77.33"}]}]}]},{"type":"SECONDARY","title":"Change in Plasma NT-pro BNP","description":"To determine the impact of oral Fe repletion on Plasma N-terminal pro-B-type natriuretic peptide (NT-pro BNP)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119.36","spread":"1937.58"},{"groupId":"OG001","value":"-70.88","spread":"1256.49"}]}]}]},{"type":"SECONDARY","title":"Change in Health Status: Kansas City Cardiomyopathy Questionnaire (KCCQ) - Clinical Summary Score","description":"To determine the impact of oral Fe repletion on Health Status: KCCQ.\n\nKCCQ is a 23-item, self administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life for patients with congestive heart failure. It is a predictive tool that tracks how patients are doing if they have weakened heart muscle due to prior heart attacks, heart valve problems, viral infections, or other causes.\n\nThe KCCQs questions are used to calculate scores in ten domains. Physical Limitation, Symptom Stability, Frequency, Burden and Total Symptom. Social Limitation, Self-Efficacy, Quality of Life, and Clinical Summary. Overall summary: a combined measure of all the above.\n\nFor each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.25","spread":"16.91"},{"groupId":"OG001","value":"0.58","spread":"13.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"16.05"},{"groupId":"OG001","value":"4.11","spread":"11.80"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in O2 Uptake Kinetics as Assessed by Mean Response Time From CPET","description":"To determine the impact of oral Fe repletion on O2 Uptake Kinetics as measured by CPET","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.63","spread":"13.31"},{"groupId":"OG001","value":"-0.95","spread":"13.29"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Ventilatory Efficiency Defined by Ve/VCO2","description":"Change from baseline in Ventilatory Efficiency defined by Ve/VCO2 (carbon dioxide output) as measured by CPET","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"5.85"},{"groupId":"OG001","value":"-1.31","spread":"8.85"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":111},"commonTop":["Diarrhoea","Constipation","Nausea","Arthralgia","Asthenia"]}}}